PRIORIX

Approved / Licensed

Developer: GlaxoSmithKline Biologicals  |  Target Disease: Measles / Mumps / Rubella

Category Resource

Explore licensed vaccines, adverse event reporting data, and history for this disease.

View Measles / Mumps / Rubella Vaccine Guide →
  1. Phase 1
  2. Phase 2
  3. Phase 3
  4. Filed
  5. Approved
Development Phase Approved / Licensed Primary Status
Platform Technology See FDA product page / label Biologic Architecture
Target Indication Measles / Mumps / Rubella Pathogen / Antigen
Last Verified 2026-10-31 Tier 1 Multi-Source Checked

Multi-Jurisdiction Regulatory Status

Official licensing, rolling submissions, or authorization status tracked across major health authorities.

Regulatory Authority Status & Details
US FDA Approved / Authorized Date: 2022-06-03FDA approval / licensure action (public FDA materials)
EMA (Europe) Not Filed / Pre-submission
Health Canada Not Filed / Pre-submission
TGA (Australia) Not Filed / Pre-submission

Progress and adoption outlook

Where this candidate sits on a fixed development ladder, and when a licence and a routine-use recommendation could follow in each jurisdiction, as scenario bands. Input grade: Regulator-confirmed status date in at least one jurisdiction.

90% of the ladderA · regulator-dated
  1. Preclinical
  2. Phase 1
  3. Phase 1/2
  4. Phase 2
  5. Phase 2/3
  6. Phase 3
  7. Submitted to a regulator
  8. Under regulatory review
  9. Approved / authorised
  10. Recommended for routine use

Current position: Approved / authorised

Status and projected windows by jurisdiction
JurisdictionStatus in the recordSubmissionRegulator decisionEarliest routine use
United StatesFDA (CBER) · ACIP (CDC)approved (2022-06-03, regulator confirmed)—2022-062022-06 to 2022-06—
European UnionEMA (CHMP) and European Commission · national bodies (STIKO, HAS, Folkhälsomyndigheten and others)no jurisdiction-specific filing known2026-102026-10 to 2026-102027-122027-07 to 2028-062028-062027-08 to 2029-12
CanadaHealth Canada · NACIno jurisdiction-specific filing known2026-102026-10 to 2026-102027-082027-04 to 2028-012027-122027-05 to 2029-01
United KingdomMHRA · JCVIno jurisdiction-specific filing knownThe MHRA 150-day national assessment and International Recognition Procedure pages could not be fetched on 2026-10-24; no target is used.
AustraliaTGA · ATAGIno jurisdiction-specific filing knownTGA registration-timeframe pages timed out on 2026-10-24; no target is used.
JapanPMDA / MHLW · MHLW immunisation subcommitteeno jurisdiction-specific filing knownPMDA English pages reached on 2026-10-24 state that target review times exist but give no figure.
WHO prequalificationWHO Prequalification · SAGEno jurisdiction-specific filing knownWHO prequalification procedure pages returned 404/500 on 2026-10-24; no target is used.

Each window shows the typical scenario with the fast-to-slow band beneath it (year-month). Bands come from the parameters on the outlook model page; they are not forecasts.

Scientific Profile & Documentation

Platform Architecture
See FDA product page / label
Lead Developer
GlaxoSmithKline Biologicals
Next Expected Milestone
US-licensed — see product label / ACIP for use; further supplements may expand indication
Analyst & Development Notes
FDA CBER licensed / approved vaccine (regulator-confirmed US listing). Second MMR vaccine licensed in the US (2022). May also have later supplements (strain updates, age expansions); see product page.
Primary Source Documentation
FDA — PRIORIX →

Registered Clinical Trials & Studies

Direct registry links to active, completed, or pivotal registration studies across phases.

No primary ClinicalTrials.gov record linked directly. Study data tracked via regulatory submission filings and peer-reviewed releases.

Milestone Overview

  • Stage Verification
    Approved / Licensed confirmed as of 2026-10-31.
  • Target Milestone
    US-licensed — see product label / ACIP for use; further supplements may expand indication

Vaccine Data Navigator Candidate Profile Registry:

This candidate profile is indexed across all clinical development levels (Preclinical through Phase 1–3, Regulatory Filing, and Licensure) from primary registry databases (ClinicalTrials.gov, WHO ICTRP, FDA CBER, EMA, Health Canada, TGA Australia). Data are updated continuously to track global biologic and vaccine pipelines.